

Beginning mid-2020, pharmaceutical manufacturers started overcharging covered entities (CEs) on 340B drugs shipped to CE contract pharmacies. This chart serves as a summary and timeline of these manufacturer restrictions.

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<b>Eli Lilly</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies; recent changes allow 340B pricing if CEs submit contract pharmacy claims data. Any covered entity that doesn't have an in-house pharmacy <a href="#">can choose a single location contract pharmacy</a> .	All covered entities (CEs)	September 1, 2020
<b>AstraZeneca</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies. <a href="#">May designate a single contract pharmacy</a> but <a href="#">each parent site</a> can have one pharmacy site for itself.	All CEs	October 1, 2020
<b>Sanofi</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that doesn't have an in-house pharmacy <a href="#">can choose a single location contract pharmacy</a> .	5 CE types: Consol, CHC, CAH, DSH, RRC, SCH	October 1, 2020
<b>Novartis</b>	Refusing 340B pricing for drugs shipped to contract pharmacies <a href="#">more than 40 miles away from hospitals' parent sites</a>	Hospitals only	November 16, 2020
<b>Novo Nordisk</b>	Refusing 340B pricing for drugs shipped to contract pharmacies.	Hospitals only	January 1, 2021



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<b><u>Can designate two contract pharmacies to receive 340B drugs</u></b> (one specialty, one regular)		
<b>United Therapeutics</b>	Phase 1: Orders for contract pharmacy drugs accepted only if CE made a “valid 340B purchase” during first three quarters of 2020. <u>Phase 2:</u> Then, refusing 340B pricing for drugs dispensed at all contract pharmacies, unless CE submits claims data.	<b>All CEs</b>	Phase 1: November 20, 2020 Phase 2: December 1, 2021
<b>Boehringer Ingelheim</b>	Will ship 340B drugs only to CEs and their child sites. Any covered entity that does not have an in-house pharmacy <b><u>can choose one contract pharmacy to receive 340B drugs.</u></b>	<b>Hospitals, CHCs</b>	August 1, 2021 <b>As of September 1, 2022: Includes health centers</b>
<b>Merck</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <b><u>can elect one contract pharmacy at a single location.</u></b>	<b>Hospitals, CHCs</b>	September 1, 2021 <b>As of May 31, 2022: Includes health centers</b>
<b>UCB</b>	Will provide 340B priced drugs to locations registered as 340B covered entities or child sites. Any covered entity that does not have an in-house pharmacy <b><u>can elect one contract pharmacy at a single location.</u></b>	Hospitals only	December 13, 2021
<b>Amgen</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies	Hospitals only	January 3, 2022



<b>Manufacturer Name</b>	<b>Type of Restriction</b>	<b>Who it Applies to</b>	<b>Effective Date</b>
	if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location (single HIN)</a>		
<b>AbbVie</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location.</a>	Hospitals only	February 1, 2022
<b>Pfizer</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location (single HIN)</a>	Hospitals only	March 1, 2022
<b>Bristol Myers Squibb</b>	Refusing 340B pricing for “non-IMiD” (Immunomodulatory imide drug) products dispensed at contract pharmacies; modifying access to 340B pricing under IMiD limited distribution network. <a href="#">Will recognize up to 2 contract pharmacies</a> (one for non-IMiDs, another for IMiDs).	Hospitals for non-IMiDs; All CEs for IMiDs	March 1, 2022
<b>GlaxoSmithKline</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any	Hospitals only	April 1, 2022



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	covered entity that does not have an in-house pharmacy may <a href="#">designate one contract pharmacy location (single HIN)</a> to have drugs shipped to.		
<b>Gilead</b>	Refusing 340B pricing for brand-name Hepatitis C drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">may designate a single contract pharmacy location</a> . Likewise, this update does not apply to contract pharmacies that are wholly owned by a covered entity or health system.	All CEs	May 2, 2022
<b>Johnson &amp; Johnson</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies; specifically: immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary arterial hypertension, and chemotherapy-induced anemia. If they choose not to submit data, <a href="#">may still designate a single contract pharmacy location (single HIN)</a> .	Hospitals only	May 2, 2022
<b>Exelixis</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies, specifically Cometriq and Cabometyx (cancer drugs). If	Hospitals only; grantees exempt “until further notice”	July 6, 2022



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	they choose not to submit data, <a href="#">may still designate a single contract pharmacy location (single HIN)</a> .		
<b>Bausch</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location (single HIN)</a>	All CEs	August 1, 2022
<b>Biogen</b>	Refusing 340B pricing for drugs, specifically Avonex and Plegridy (which treat multiple sclerosis), dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <a href="#">designate one contract pharmacy location (single HIN)</a> to have drugs shipped to.	Hospitals only	February 1, 2023
<b>Bayer</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <a href="#">designate one contract pharmacy (single HIN)</a> to have drugs shipped to. Drugs excluded from this restriction, for now, include: Adempas, Aliqopa, Jivi, Kerendia, Kogenate, Kovaltry,	Hospitals only	March 1, 2023



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	Kyleena, Lampit, Mirena, Skyla, Nubeqa, Xofigo.		
<b>EMD Serono</b>	Refusing 340B pricing for drugs, specifically Refib (interferon beta-1a) and Gonal-f (follitropin alfa for injection), dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <b><u>designate one contract pharmacy location (single HIN)</u></b> to have drugs shipped to.	Hospitals only	March 1, 2023